US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lakewood-Amedex Biotherapeutics (Direct Listing)

0.3861

-0.2161-35.89%

Post-market: 0.39200.0059+1.53%19:49 EDT

Volume:1.83M

Turnover:778.91K

Market Cap:5.53M

PE:-1.31

High:0.5895

Open:0.5630

Low:0.3660

Close:0.6022

52wk High:9.82

52wk Low:0.3660

Shares:14.32M

Float Shares:4.70M

Volume Ratio:5.03

T/O Rate:38.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2950

EPS(LYR):-0.8399

ROE:--

ROA:-303.80%

PB:-2.81

PE(LYR):-0.46

Loading ...

Overview Company News Filings

Lakewood-Amedex Biotherapeutics - Announces 1-for-10 Reverse Stock Split of Common Stock - SEC Filing

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics CEO presents at Life Sciences Virtual Investor Forum

Lakewood-Amedex Biotherapeutics building broad antimicrobial platform, CEO says

Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper

Lakewood-Amedex Biotherapeutics issued two new patents

Lakewood-Amedex wins Australia, New Zealand patents for Nu-3 diabetic foot ulcer gel formulation

Lakewood-Amedex Q1 FY26 net loss widens to $923,291

Lakewood-Amedex advances Nu-3 gel toward Phase 2 trial in infected diabetic foot ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics : Key Formulation, Delivery and Manufacturing Steps Completed in Preparation for Planned Phase 2 Clinical Trial

THOMSON REUTERS

Lakewood-Amedex taps PERI as CRO for Nu-3 Phase 2 diabetic foot ulcer trial

Lakewood-Amedex Biotherapeutics Announces Agreement With Peri to Serve as Cro for Phase 2 Clinical Trial of Nu-3

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics director Joseph Tucker files initial beneficial ownership statement

Lakewood-Amedex files Form 3 for CEO, director Kelvin Cooper

Lakewood-Amedex Biotherapeutics’ lead candidate in foot ulcers shows efficacy

Lakewood-Amedex reports positive antimicrobial resistance data for Nu-3 diabetic foot ulcer drug

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Inc - Nu-3 Maintains Activity Against Ciprofloxacin-Resistant Bacteria

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics names Enveric CEO Joseph Tucker to board

Press Release: Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LABT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":0.3861,"timestamp":1781812800000,"preClose":0.6022,"halted":3,"volume":1830790,"hourTrading":{"tag":"盘后","latestPrice":0.392,"preClose":0.3861,"latestTime":"19:49 EDT","volume":348281,"amount":143405.323819,"timestamp":1781826588480,"change":0.0059,"changeRate":0.015281,"amplitude":0.240611},"delay":0,"changeRate":-0.3588508801062769,"floatShares":4700000,"shares":14320400,"eps":-0.295,"marketStatus":"Halted","change":-0.2161,"latestTime":"06-18 16:00:00 EDT","open":0.563,"high":0.589499,"low":0.366,"amount":778912.2235297001,"amplitude":0.371137,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.295,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":5,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":0.6022,"preHourTrading":{"tag":"盘前","latestPrice":0.572,"preClose":0.614,"latestTime":"09:29 EDT","volume":21539,"amount":12121.554723599998,"timestamp":1781789349300,"change":-0.042,"changeRate":-0.068404,"amplitude":0.031922},"postHourTrading":{"tag":"盘后","latestPrice":0.392,"preClose":0.3861,"latestTime":"19:49 EDT","volume":348281,"amount":143405.323819,"timestamp":1781826588480,"change":0.0059,"changeRate":0.015281,"amplitude":0.240611},"volumeRatio":5.025763},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":4700000,"roa":"-303.80%","roe":"--","lyrEps":-0.839872,"volumeRatio":5.025763,"shares":14320400,"dividePrice":0,"high":0.589499,"amplitude":0.371137,"preClose":0.6022,"low":0.366,"week52Low":0.366,"pbRate":"-2.81","week52High":9.82,"institutionHeld":0,"latestPrice":0.3861,"eps":-0.295,"divideRate":0,"volume":1830790,"delay":0,"ttmEps":-0.295,"open":0.563,"prevYearClose":8,"prevWeekClose":0.7674,"prevMonthClose":0.675,"prevQuarterClose":8,"fiveDayClose":0.7228,"twentyDayClose":0.753},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-06-17","current":-1.308814,"percent":0.566667,"low":-12.282138,"twenty":-11.537766,"median":-2.80256,"eighty":-2.512255,"high":-2.307553,"avg":-5.268076,"sd":3.93728,"marketCap":10511148},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-17","current":-2.731845,"twenty":-11.537766,"median":-2.80256,"eighty":-2.512255,"marketCap":10511148}],"updateTime":1781817812526},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644747205","title":"Lakewood-Amedex Biotherapeutics - Announces 1-for-10 Reverse Stock Split of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644747205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644747205?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:41","pubTimestamp":1781710915,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42P0CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754791","title":"Lakewood-Amedex Biotherapeutics CEO presents at Life Sciences Virtual Investor Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754791?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:04","pubTimestamp":1781611444,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics will present at the Life Sciences Virtual Investor Forum on June 25, 2026, at 11:30 a.m. EDT.CEO Kelvin Cooper is scheduled to discuss the company’s growth strategy, including its Nu-3 topical gel program for infected diabetic foot ulcers.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL2tcnsK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639167489","title":"Lakewood-Amedex Biotherapeutics building broad antimicrobial platform, CEO says","url":"https://stock-news.laohu8.com/highlight/detail?id=2639167489","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639167489?lang=en_us&edition=fundamental","pubTime":"2026-05-30 02:11","pubTimestamp":1780078300,"startTime":"0","endTime":"0","summary":"14:00 EDT Lakewood-Amedex Biotherapeutics (LABT) building broad antimicrobial platform, CEO says Published first on TheFly – the ultimate source fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-building-broad-antimicrobial-platform-ceo-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-building-broad-antimicrobial-platform-ceo-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639674811","title":"Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper","url":"https://stock-news.laohu8.com/highlight/detail?id=2639674811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639674811?lang=en_us&edition=fundamental","pubTime":"2026-05-30 02:05","pubTimestamp":1780077931,"startTime":"0","endTime":"0","summary":"In an exclusive interview, Lakewood‑Amedex Biotherapeutics (LABT) CEO Kelvin Cooper spoke with The Fly about the company, going public, its Bisphos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/meet-lakewood-amedex-biotherapeutics-fly-exclusive-with-ceo-kelvin-cooper-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/meet-lakewood-amedex-biotherapeutics-fly-exclusive-with-ceo-kelvin-cooper-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GB00BDT5M118.USD","LU2211815571.USD","BK4198","COO","BK4139","LABT","BK4588","LU2272731782.SGD","LU2272731600.USD","BK4585","LU1992135472.HKD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638891926","title":"Lakewood-Amedex Biotherapeutics issued two new patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2638891926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638891926?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:34","pubTimestamp":1779892465,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced an expansion of its global intellectual property portfolio with the issuance of two patents, one e...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-issued-two-new-patents-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-issued-two-new-patents-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638077335","title":"Lakewood-Amedex wins Australia, New Zealand patents for Nu-3 diabetic foot ulcer gel formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2638077335","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638077335?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:04","pubTimestamp":1779883444,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics secured new gel-formulation patents for Bisphosphocin Nu-3 in Australia and New Zealand.New Zealand granted patent 759577 on Feb. 3, 2026; Australia granted patent 2024202211 on March 19, 2026.Patents cover Nu-3 topical gel formulation; Nu-3 is being advanced into a Phase 2 trial for mildly infected diabetic foot ulcers.Nu-3 gel formulation portfolio now totals 27 granted patents; overall IP estate totals 71 granted patents with 28 pending applications.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL1k5Vfk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637344005","title":"Lakewood-Amedex Q1 FY26 net loss widens to $923,291","url":"https://stock-news.laohu8.com/highlight/detail?id=2637344005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637344005?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:55","pubTimestamp":1779483358,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics posted a net loss of USD 923,291 for the quarter ended March 31, 2026, widening from USD 539,617 a year earlier.Operating loss widened to USD 886,750 as operating expenses rose to USD 886,750 from USD 542,609.General and administrative costs climbed to USD 704,603 from USD 372,906, driven by higher professional fees and investor relations spending tied to preparation for a proposed Nasdaq direct listing.Research and development spending edged up to USD 182,147 from USD 169,703, while net interest expense increased as interest expense rose to USD 38,219 from USD 1,315.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL8mw7NB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636807358","title":"Lakewood-Amedex advances Nu-3 gel toward Phase 2 trial in infected diabetic foot ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636807358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636807358?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:05","pubTimestamp":1779105903,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics reported positive development data for its lead candidate Nu-3 as it moves toward a planned Phase 2 trial in mildly infected diabetic foot ulcers.The update covered completed formulation, delivery, and cGMP manufacturing work intended to support clinical supply for the Phase 2 program.Stability and product-quality testing indicated the drug substance and gel formulation remained usable over extended storage periods, supporting trial readiness.The company positioned Nu-3 as a topical antimicrobial designed to lower the risk of resistance, with broader potential across other infectious-disease settings.Results have already been presented in this announcement, with the Phase 2 trial expected to be run in the future.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbv4Y9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078054","title":"Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078054?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:02","pubTimestamp":1779105770,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073393","title":"Lakewood-Amedex Biotherapeutics : Key Formulation, Delivery and Manufacturing Steps Completed in Preparation for Planned Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073393?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:02","pubTimestamp":1779105770,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216060","title":"Lakewood-Amedex taps PERI as CRO for Nu-3 Phase 2 diabetic foot ulcer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216060","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216060?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:04","pubTimestamp":1778587484,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics entered agreement with Professional Education and Research Institute  to act as contract research organization for upcoming Phase 2 clinical program of Nu-3 in mildly infected diabetic foot ulcers.Partnership targets Phase 2a single-blinded study comparing 2%, 5%, 10% Nu-3 gel concentrations, followed by Phase 2b testing once-daily or twice-daily dosing versus placebo.Collaboration positions PERI’s wound-care investigator network to support site access, patient recruitment, data generation as Nu-3 advances toward potential registration pathway.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL9Dx8T7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634521640","title":"Lakewood-Amedex Biotherapeutics Announces Agreement With Peri to Serve as Cro for Phase 2 Clinical Trial of Nu-3","url":"https://stock-news.laohu8.com/highlight/detail?id=2634521640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634521640?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:02","pubTimestamp":1778587320,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA9YKL9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633165676","title":"Lakewood-Amedex Biotherapeutics director Joseph Tucker files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633165676","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633165676?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:34","pubTimestamp":1778106879,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics reported Joseph Edward Tucker filed an initial Form 3 as a director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL5yWtgS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632628056","title":"Lakewood-Amedex files Form 3 for CEO, director Kelvin Cooper","url":"https://stock-news.laohu8.com/highlight/detail?id=2632628056","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632628056?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:46","pubTimestamp":1777671963,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper filed Form 3 reporting direct ownership of 300,594 common shares as of April 17, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL4D12nt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632961445","title":"Lakewood-Amedex Biotherapeutics’ lead candidate in foot ulcers shows efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2632961445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632961445?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:13","pubTimestamp":1777637622,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced positive antimicrobial resistance, or AMR, data for its lead compound, Nu-3, which is being develo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-lead-candidate-in-foot-ulcers-shows-efficacy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-lead-candidate-in-foot-ulcers-shows-efficacy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632614383","title":"Lakewood-Amedex reports positive antimicrobial resistance data for Nu-3 diabetic foot ulcer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2632614383","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632614383?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:04","pubTimestamp":1777637057,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics announced positive laboratory resistance findings for Nu-3, its lead topical candidate for infected diabetic foot ulcers.Results have already been generated from studies designed to promote resistance over 21 days.Nu-3 largely retained antimicrobial activity in these tests, supporting company expectations for low resistance risk versus standard antibiotics.Data also indicated no cross-resistance in bacteria that became resistant to ciprofloxacin, reinforcing Nu-3 positioning for drug-resistant infections.Lakewood-Amedex is also evaluating its Bisphosphocin class in preclinical work for complicated urinary tract infection and pulmonary infections.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL3TTv77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632829614","title":"Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2632829614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632829614?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:02","pubTimestamp":1777636930,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nFWN41D1TJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632161482","title":"Lakewood-Amedex Biotherapeutics Inc - Nu-3 Maintains Activity Against Ciprofloxacin-Resistant Bacteria","url":"https://stock-news.laohu8.com/highlight/detail?id=2632161482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632161482?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:02","pubTimestamp":1777636930,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nFWN41D1TJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631562539","title":"Lakewood-Amedex Biotherapeutics names Enveric CEO Joseph Tucker to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2631562539","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631562539?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:51","pubTimestamp":1777409464,"startTime":"0","endTime":"0","summary":"Tucker serves as chief executive officer and director of Enveric Biosciences.His background includes more than two decades of biotech leadership across public and private companies, spanning discovery through late-stage drug development.Previous roles include chief executive officer, executive chairman, and director positions at Willow Biosciences and Stem Cell Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL8ZSsWt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4007","ENVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630267306","title":"Press Release: Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2630267306","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630267306?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:33","pubTimestamp":1777375980,"startTime":"0","endTime":"0","summary":"Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing. SARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., , a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences , to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance and strategic capabilities as it advances its growth strategy.Dr. Tucker commented: \"I am excited to join the Board of Lakewood-Amedex Biotherapeutics at such an important moment in the Company's evolution. The recent Nasdaq listing positions the Company for its next phase of growth, and I am particularly encouraged by the","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","R","LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}